The company had to pause the study because of the COVID-19 pandemic. The results come about a month after Pixium Vision backed out of acquiring Second Sight. Pixium walked away from the deal because it said Second Sight violated a memorandum of understanding between the two.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,